Volume 63, Pages S32-S38 (June 2003)

Slides:

Advertisements

Similar presentations

Volume 68, Pages S24-S28 (July 2005)

Advertisements

Parathyroidectomy: Whom and when?

Volume 54, Pages S135-S139 (December 1998)

Volume 67, Pages S1-S7 (June 2005)

Anemia management in chronic kidney disease

Epidemiology of diabetic nephropathy in Spain

Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients Demetrios J. Kutsogiannis, R.T.Noel.

Volume 67, Issue 6, Pages (June 2005)

Parathyroidectomy: Whom and when?

Progression of renal failure and hypertensive nephrosclerosis

Volume 63, Pages S88-S90 (June 2003)

M. Fukagawa, S. Nakanishi, J.J. Kazama Kidney International

Chimeric RNA/DNA oligonucleotide-based gene therapy

George A. Kaysen, Burl R. Don

Comorbidity and confounding in end-stage renal disease

Body weight is a fluctuating parameter in hemodialysis patients

D. Coyne Kidney International Volume 69, Pages S1-S3 (May 2006)

Paricalcitol therapy for secondary hyperparathyroidism in patients on maintenance hemodialysis previously treated with calcitriol: A single-center crossover.

Edmund G. Lowrie Kidney International

Immunoglobulin light chains in uremia

Study of Heart and Renal Protection (SHARP)

Acute myocardial infarction in patients with end-stage renal disease

The calcium–phosphorus in guidelines for CKD-MBD

Public health in Africa: What is new—The context, the gains, the losses, the renewed public health, and the way forward D.A.N.C.O. Kaseje, Pamela Juma,

Anemia as a risk factor for cardiovascular disease

Blood pressure targets in hemodialysis patients

Volume 68, Pages S24-S28 (July 2005)

Volume 67, Pages S63-S68 (January 2005)

Volume 63, Pages S115-S118 (June 2003)

Volume 73, Issue 12, Pages (June 2008)

Volume 74, Pages S88-S93 (December 2008)

Volume 75, Issue 11, Pages (June 2009)

Volume 56, Pages S31-S37 (December 1999)

New insights in uremic toxins

Volume 69, Issue 12, Pages (June 2006)

Volume 69, Issue 3, Pages (February 2006)

Volume 63, Pages S38-S42 (February 2003)

Nephrology in Latin America, with special emphasis on Brazil

Alternate-day dialysis may be needed for hemodialysis patients

Juan M. Lopez-Gomez, Eduardo Verde, Rafael Perez-Garcia

AGEs in foods: Do they play a role in uremia?

Simvastatin in nephrotic syndrome

Pathogenesis of refractory secondary hyperparathyroidism

Nephrology Crossword: Glomerulonephritis

Treatment of hyperphosphatemia with sevelamer hydrochloride in dialysis patients: effects on vascular calcification, bone and a close look into the survival.

Michael W. Steffes, Derek Schmidt, Rebecca Mccrery, John M. Basgen

Volume 54, Pages S135-S139 (December 1998)

Homocysteine, renal function, and risk of cardiovascular disease

Volume 54, Issue 1, Pages (July 1998)

Volume 53, Issue 5, Pages (May 1998)

Volume 63, Pages S79-S82 (June 2003)

Taking a public health approach to the prevention of end-stage renal disease: The NKF Singapore Program Sylvia Paz B. Ramirez, Stephen I-Hong Hsu, William.

Organ transplantation goes to the movies

Volume 70, Pages S84-S90 (November 2006)

Stephen P. Mcdonald, Graeme R. Russ Kidney International

Volume 55, Pages S3-S16 (June 1999)

Volume 68, Pages S98-S102 (December 2005)

Charles A. Herzog Kidney International

Volume 71, Issue 9, Pages (May 2007)

Renal replacement therapy in Latin America

Volume 70, Issue 5, Pages (September 2006)

The international realities of live donor kidney transplantation

Strategies for iron supplementation: Oral versus intravenous

The International Pediatric Peritonitis Registry: Starting to walk

Relationship between advanced glycoxidation end products, inflammatory markers/acute-phase reactants, and some autoantibodies in chronic hemodialysis.

Recombinant hirudin (lepirudin) as anticoagulant in intensive care patients treated with continuous hemodialysis Karl-Georg Fischer, M.D., Andreas van.

Abby S. Kazley, Kit N. Simpson, Kenneth D. Chavin, Prabhakar Baliga

Volume 55, Pages S41-S46 (June 1999)

Asymmetric dimethylarginine: A cardiovascular risk factor in renal disease? Danilo Fliser, Jan T. Kielstein, Hermann Haller, Stefanie M. Bode-Böger Kidney.

Volume 64, Pages S131-S136 (November 2003)

Presentation transcript:

Volume 63, Pages S32-S38 (June 2003) Chromosomal aberrations, the consequence of refractory hyperparathyroidism: Its relationship with biochemical parameters Sandra Afonso, Íñigo Santamaría, Martín E. Guinsburg, Ana Otero Gómez, José Luis García Miranda, Rosa Jofré, Javier Menárguez, Jorge Cannata-Andía, Juan C. Cigudosa Kidney International Volume 63, Pages S32-S38 (June 2003) DOI: 10.1046/j.1523-1755.63.s85.9.x Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 1 DNA copy number changes in 57 parathyroid glands from 22 patients with refractory secondary hyperparathyroidism. Each vertical bar on the left side of each chromosome represents a loss in a particular gland and indicates the size and localization of the change. Each bar on the right side of the chromosome represents a gain of DNA of that particular chromosome or chromosomal region. Kidney International 2003 63, S32-S38DOI: (10.1046/j.1523-1755.63.s85.9.x) Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 2 DNA copy number changes in 28 parathyroid glands from 13 patients with refractory hyperparathyroidism after kidney transplantation. Each vertical bar on the left side of each chromosome represents a loss in a particular gland and indicates the size and localization of the change. Each bar on the right side of the chromosome represents a gain of DNA of that particular chromosome or chromosomal region. Kidney International 2003 63, S32-S38DOI: (10.1046/j.1523-1755.63.s85.9.x) Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 3 Relationship between the levels of P and Ca and the presence or absence of chromosomal aberrations. (A) Glands considered independently and (B) data grouped according to the patients. Light gray square = normal range of values for P. Dark gray square = normal range of values for Ca. *P < 0.05 Kidney International 2003 63, S32-S38DOI: (10.1046/j.1523-1755.63.s85.9.x) Copyright © 2003 International Society of Nephrology Terms and Conditions